Nordhealth AS (OSL:NORDH) Marketable Securities: kr74.3 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSL:NORDH Nordhealth AS OSL:NORDH
76 GF Score
Price kr24.20
GF Value kr38.51
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Nordhealth AS Marketable Securities?

Nordhealth AS OSL:NORDH +1.68% 76 Marketable Securities is kr74.3 Mil as of Jun. 2026. GuruFocus rates OSL:NORDH with a GF Score™ of 76/100 and a GF Value™ of kr38.51 (Significantly Undervalued). The stock has 1 warning sign investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Nordhealth AS's Marketable Securities for the quarter that ended in Jun. 2026 was kr74.3 Mil.

Nordhealth AS's annual Marketable Securities declined from Dec. 2023 (kr196.9 Mil) to Dec. 2024 (kr182.4 Mil) and declined from Dec. 2024 (kr182.4 Mil) to Dec. 2025 (kr122.4 Mil).

Nordhealth AS  (OSL:NORDH) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Nordhealth AS Marketable Securities Related Terms

Nordhealth AS Marketable Securities Historical Data

* Premium members only.

The historical data trend for Nordhealth AS's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nordhealth AS Marketable Securities Chart

Nordhealth AS Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 471.46 247.88 196.94 182.43 122.41

Nordhealth AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 156.39 140.92 122.41 74.58 74.29
OSL:NORDH
76GF Score
Nordhealth AS OSL:NORDH
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nordhealth AS Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of kr74.3 Mil mean?
Nordhealth AS (OSL:NORDH) has a Marketable Securities of kr74.3 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Nordhealth AS and its competitors.
Is Nordhealth AS's Marketable Securities too high?
Nordhealth AS's current Marketable Securities is kr74.3 Mil. Overall, Nordhealth AS has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nordhealth AS's Marketable Securities compare to VEEV and BTSG?
Nordhealth AS's Marketable Securities of kr74.3 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Healthcare Providers & Services company?
A good Marketable Securities depends on the Healthcare Providers & Services industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Nordhealth AS and its competitors. Nordhealth AS's current Marketable Securities is kr74.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nordhealth AS stock overvalued right now?
Based on GuruFocus' analysis, Nordhealth AS (OSL:NORDH) is currently considered Significantly Undervalued. The stock's GF Value™ is kr38.51, compared to a current price of kr24.20 — trading 37.2% below its estimated fair value. The current Marketable Securities is kr74.3 Mil. Nordhealth AS's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Nordhealth AS (OSL:NORDH), the current Marketable Securities is kr74.3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nordhealth AS (OSL:NORDH) Overvalued in 2026?

Based on GuruFocus' analysis, Nordhealth AS stock appears to be undervalued. The current stock price of kr24.20 is trading 37.2% below its estimated GF Value™ of kr38.51. GuruFocus considers Nordhealth AS to be Significantly Undervalued.

Key valuation signals for OSL:NORDH:

  • Marketable Securities: kr74.3 Mil
  • GF Value™: kr38.51 vs. price of kr24.20 (37.2% below fair value)
  • GF Score™: 76/100 with 1 warning sign

No single metric tells the full story. See the OSL:NORDH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nordhealth AS Business Description

Address Hasleveien 28A, Oslo, NOR, 0571
Nordhealth AS is a cloud-based healthcare Software-as-a-Service business. Its flagship Practice Management Software (PMS), Provet for veterinary practices and Therapy Unified Platform for therapy practices, assist healthcare professionals to streamline operations and improve patient care. The majority of its revenue is generated through software subscriptions. The Group also offers additional services related to the implementation of the SaaS systems, including consultancy services, education, and data conversion. Its operating segments are: Veterinary, which generates the majority of revenue, Therapy, and Other. Geographically, Nordhealth derives maximum revenue from Norway, and the rest from Finland, the United Kingdom, Sweden, Denmark, the DACH region, and other countries.
76GF Score

Get the complete analysis for OSL:NORDH

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr24.20
Price
kr38.51
GF Value